drugset / Trial / NCT06456567
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
Timeline
- Start
- 2024-09
- Primary completion
- 2025-01-02
- Completion
- 2025-01-06
Outcome
Outcome not reported
Stopped (Business): “Sponsor business decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | — | Subcutaneous |